Abstract
To optimize and assess an abbreviated dual time-point 18-Fluor-Deoxyglucose (FDG)-Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) protocol for predicting patient outcomes in pancreatic cancer. 70 patients (47 pancreatic cancer, 23 chronic pancreatitis) underwent hybrid PET/MRI with dual time-point PET/CT at 60 and 84 minutes post-injection. Metabolic indices (MI) were calculated from Standardized Uptake Value (SUV) changes (SUVmin, SUVmean and SUVmax). Multivariate analysis was performed on PET, MRI, laboratory, and histologic data. Top predictors were used for survival analysis. MI SUVmax, thresholded at 11%, was the best outcome predictor, distinguishing high-risk (2year (2y)-Overall Survival (OAS) 32%, 5y-OAS 14%, 10y-OAS 8%) and low-risk groups (2y-OAS 76%, 5y-OAS 32%, 10y-OAS 23%). Tumor size, CBD obstruction, and infiltrative disease had lower predictive value. Metabolic indices from abbreviated dual time-point FDG-PET/MRI can differentiate pancreatic malignancy from pancreatitis and predict outcomes, outperforming other indices. This protocol offers a valuable diagnostic tool for characterizing pancreatic lesions and predicting outcomes based on imaging criteria.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call